Neurognostics, Inc. Awarded SBIR Grant To Develop fMRI Bio-Markers
10/19/2005 5:09:00 PM
Neurognostics, Inc., a functional Magnetic Resonance Imaging (fMRI) service company, received notification of funding from the National Institutes of Health (NIH) for its Small Business Innovative Research (SBIR) Grant. The grant will support the development of fMRI bio-markers which Neurognostics will use to study Parkinson's patients both on and off medications.
The principal investigator, Cathy Elsinger, Ph.D., Director of Research at Neurognostics, will work with Stephen M. Rao, Ph.D. of the Medical College of Wisconsin to meet the objectives of the Phase I study grant. The results of the Phase I study will be used to support an expanded Phase II research program.
comments powered by